Sharon Adams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sharon Adams has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Deborah Chen
Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
2 shared publications - Francesco M Marincola
Kite Pharma, Santa Monica, CA 90404, USA
2 shared publications - Aladar A. Szalay
Institute for Molecular Infection Biology, University of Wuerzburg, D-97078 Wuerzburg, Germany
1 shared publication - Andrea Worschech
Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and trans-NIH Center of Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA
1 shared publication - David F. Stroncek
Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD, USA
1 shared publication - David F. Stroncek
Department of Transfusion Medicine and Center for Cellular Engineering Clinical Center, National Institutes of Health Bethesda Maryland USA
1 shared publication
Latest Publications
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 191
P179 Multi-center study on automating holotype HLA on a Biomek 4000
- 1 September 2017
- Published by Elsevier in Human Immunology
- Vol. 78, 191
P179 Multi-center study on automating holotype HLA on a Biomek 4000
- Open Access
- 19 October 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 1-14
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo. In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection. We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection. Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
- 19 October 2011
- Published by Springer Nature in BMC Cancer
- Vol. 11 (1) , 1-14
Open AccessPermissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68
Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo. In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection. We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection. Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.
- 31 October 2008
- Published by Elsevier in Human Immunology
- Vol. 69, S54
94-P: KIR genes in Tunisians with nasopharyngeal carcinoma
- 31 October 2008
- Published by Elsevier in Human Immunology
- Vol. 69, S54
94-P: KIR genes in Tunisians with nasopharyngeal carcinoma
- Open Access
- 4 March 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 11
HLA class I and II genotype of the NCI-60 cell lines
Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.
- 4 March 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 11
Open AccessHLA class I and II genotype of the NCI-60 cell lines
Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.